Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Shafi, T., Sirich, T. L., Meyer, T. W., Hostetter, T. H., Plummer, N. S., Hwang, S., Melamed, M. L., Banerjee, T., Coresh, J., & Powe, N. R. Kidney International, 92(6):1484--1492, December, 2017. doi abstract bibtex Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63% were Black and 42% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12% higher risk of cardiac death (hazard ratio 1.12; 95% confidence interval, 0.98-1.27) and 22% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.
@article{shafi_results_2017,
title = {Results of the {HEMO} {Study} suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes},
volume = {92},
issn = {1523-1755},
doi = {10.1016/j.kint.2017.05.012},
abstract = {Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63\% were Black and 42\% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12\% higher risk of cardiac death (hazard ratio 1.12; 95\% confidence interval, 0.98-1.27) and 22\% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22\% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.},
language = {eng},
number = {6},
journal = {Kidney International},
author = {Shafi, Tariq and Sirich, Tammy L. and Meyer, Timothy W. and Hostetter, Thomas H. and Plummer, Natalie S. and Hwang, Seungyoung and Melamed, Michal L. and Banerjee, Tanushree and Coresh, Josef and Powe, Neil R.},
month = dec,
year = {2017},
pmid = {28739139},
pmcid = {PMC5696072},
keywords = {cardiovascular mortality, dialysis outcomes, hippurate, indoxyl sulfate, p-cresol sulfate, phenylacetylglutamine},
pages = {1484--1492}
}
Downloads: 0
{"_id":"XRm9LLbWYMuwqPHBs","bibbaseid":"shafi-sirich-meyer-hostetter-plummer-hwang-melamed-banerjee-etal-resultsofthehemostudysuggestthatpcresolsulfateandindoxylsulfatearenotassociatedwithcardiovascularoutcomes-2017","downloads":0,"creationDate":"2018-04-17T15:45:25.388Z","title":"Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes","author_short":["Shafi, T.","Sirich, T. L.","Meyer, T. W.","Hostetter, T. H.","Plummer, N. S.","Hwang, S.","Melamed, M. L.","Banerjee, T.","Coresh, J.","Powe, N. R."],"year":2017,"bibtype":"article","biburl":"https://api.zotero.org/groups/917610/items?key=5Tpdn4Dba9sBkYSJL5LXwhhi&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes","volume":"92","issn":"1523-1755","doi":"10.1016/j.kint.2017.05.012","abstract":"Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63% were Black and 42% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12% higher risk of cardiac death (hazard ratio 1.12; 95% confidence interval, 0.98-1.27) and 22% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.","language":"eng","number":"6","journal":"Kidney International","author":[{"propositions":[],"lastnames":["Shafi"],"firstnames":["Tariq"],"suffixes":[]},{"propositions":[],"lastnames":["Sirich"],"firstnames":["Tammy","L."],"suffixes":[]},{"propositions":[],"lastnames":["Meyer"],"firstnames":["Timothy","W."],"suffixes":[]},{"propositions":[],"lastnames":["Hostetter"],"firstnames":["Thomas","H."],"suffixes":[]},{"propositions":[],"lastnames":["Plummer"],"firstnames":["Natalie","S."],"suffixes":[]},{"propositions":[],"lastnames":["Hwang"],"firstnames":["Seungyoung"],"suffixes":[]},{"propositions":[],"lastnames":["Melamed"],"firstnames":["Michal","L."],"suffixes":[]},{"propositions":[],"lastnames":["Banerjee"],"firstnames":["Tanushree"],"suffixes":[]},{"propositions":[],"lastnames":["Coresh"],"firstnames":["Josef"],"suffixes":[]},{"propositions":[],"lastnames":["Powe"],"firstnames":["Neil","R."],"suffixes":[]}],"month":"December","year":"2017","pmid":"28739139","pmcid":"PMC5696072","keywords":"cardiovascular mortality, dialysis outcomes, hippurate, indoxyl sulfate, p-cresol sulfate, phenylacetylglutamine","pages":"1484--1492","bibtex":"@article{shafi_results_2017,\n\ttitle = {Results of the {HEMO} {Study} suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes},\n\tvolume = {92},\n\tissn = {1523-1755},\n\tdoi = {10.1016/j.kint.2017.05.012},\n\tabstract = {Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63\\% were Black and 42\\% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12\\% higher risk of cardiac death (hazard ratio 1.12; 95\\% confidence interval, 0.98-1.27) and 22\\% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22\\% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.},\n\tlanguage = {eng},\n\tnumber = {6},\n\tjournal = {Kidney International},\n\tauthor = {Shafi, Tariq and Sirich, Tammy L. and Meyer, Timothy W. and Hostetter, Thomas H. and Plummer, Natalie S. and Hwang, Seungyoung and Melamed, Michal L. and Banerjee, Tanushree and Coresh, Josef and Powe, Neil R.},\n\tmonth = dec,\n\tyear = {2017},\n\tpmid = {28739139},\n\tpmcid = {PMC5696072},\n\tkeywords = {cardiovascular mortality, dialysis outcomes, hippurate, indoxyl sulfate, p-cresol sulfate, phenylacetylglutamine},\n\tpages = {1484--1492}\n}\n\n","author_short":["Shafi, T.","Sirich, T. L.","Meyer, T. W.","Hostetter, T. H.","Plummer, N. S.","Hwang, S.","Melamed, M. L.","Banerjee, T.","Coresh, J.","Powe, N. R."],"key":"shafi_results_2017","id":"shafi_results_2017","bibbaseid":"shafi-sirich-meyer-hostetter-plummer-hwang-melamed-banerjee-etal-resultsofthehemostudysuggestthatpcresolsulfateandindoxylsulfatearenotassociatedwithcardiovascularoutcomes-2017","role":"author","urls":{},"keyword":["cardiovascular mortality","dialysis outcomes","hippurate","indoxyl sulfate","p-cresol sulfate","phenylacetylglutamine"],"downloads":0},"search_terms":["results","hemo","study","suggest","cresol","sulfate","indoxyl","sulfate","associated","cardiovascular","outcomes","shafi","sirich","meyer","hostetter","plummer","hwang","melamed","banerjee","coresh","powe"],"keywords":["cardiovascular mortality","dialysis outcomes","hippurate","indoxyl sulfate","p-cresol sulfate","phenylacetylglutamine"],"authorIDs":[],"dataSources":["mpYZnowFZJzNgjyys"]}